ERBB2 and breast cancer: The identification of mutational drivers remains the biggest challenge, because, with few exceptions, such as estrogen receptor (ER) or human epidermal growth factor receptor 2 (HER2), no other validated oncogenic drivers of BC tumorigenesis exist.